MORE THAN 50% OF CLVS SHARES ARE ILLEGALLY HELD

Pat Mahaffy, Ginger Graham, and others are named offenders in a stock scam that has lasted since the summer of 2019 as these freaking criminal idiots have sold parcel after parcel after parcel to the company that is buying Clovis Oncology. Hedge Fund Palo Alto has sent out a presentation to their clients documenting stock surveillance reports that began all the way back in 2020 after Mahaffy’s fraudulent criminal lies regarding the stock and an offer made to the board for the company at that time.

The presentation is quite exhaustive and lengthy, but the summary is this simple. Pat Mahaffy and Ginger Graham have engineered illegal securities fraud through undisclosed transactions all tied to a several year scheme that would drive down the price of the stock, while they hand themselves millions of shares, only to arrive in 2022 and then
magically declare that there is an offer for the company and the board has accepted it. Mahaffy, Graham, and the rest of the criminal board members have stolen billions from shareholders of CLVS during the lengthy amount of time that has passed during their illegal scheme.

 

"June 2019 at the Annual Shareholder Meeting for CLVS a proposal was approved to increase the share count ceiling from 100M shares to 200M shares. At the time CLVS had just 53M shares outstanding, needed less 4M shares earmarked for convertible note holders at that time, and had only increased their outstanding share count by 19M shares in the prior 4.5 years COMBINED. CLVS was $23.50 in April 2019 when that was proposed. There was no legit business reason that 200M shares were suddenly needed, but the proposal passed. Just 2 months later, Mahaffy elected to pass out 2024 convertible notes for CLVS financing despite half a dozen other options that were not dilutive and had the same if not better terms for CLVS/Shareholders. Before the 1st payment was even due on the notes, the scumbag Mahaffy, Highbridge (JP Morgan) and State Street went to work with enormous conversions of almost 18M shares to backstop shorts that were staring down heavy losses from the unexpected Q4’19 run."